Tuesday, November 18, 2025 2:17:26 PM
Doc Logic,
Thank you for answering directly. Let me stay focused on the single point you raised.
You asked why NWBO did not explicitly state “C grade fitting complete.” The reason is that they do not have to say it. Once SOW 8 was marked complete, and once Advent passed both the MIA IMP inspection and the full commercial MIA inspection, the regulatory conclusion is already in place. MHRA does not license ATMP manufacturing on plans or future intentions. They license only what is built, qualified and inspected at the time of review.
That is why the filings can openly discuss a future simplified C lab for Eden while the current licensed footprint already supports the upstream work required for L and Direct. The existence of C grade capability is a regulatory prerequisite, not a marketing statement. It sits inside the license, not inside a press release.
You already understand the SOW 8 chain and the London chain, so I will touch them only lightly. The upstream portion of SOW 8 cannot occur in B grade alone. It requires C grade space. And Specials/Compassionate Use production in London, years before Sawston required the same C grade capabilities. Both events happened. Both required functioning C grade environments. That is the factual anchor.
What this discussion has really done is bring something else to the surface that the filings never state outright but clearly imply.
NWBO has been preparing for scale long before approval.
It is visible everywhere once you look through that lens.
The phased Sawston buildout, the multiple SOW milestones, the acquisition of Advent, the Flaskworks development program, the simplified C lab design for automated scale, the redevelopment of the Grade B suites, and the internal language about preparing the facility for commercialization, all of it points to the same thing. They have already done the majority of the foundational work needed for rapid expansion once Eden is validated.
That is unusual in this space. Most companies wait for approval and then begin thinking about capacity. NWBO inverted that timeline. They built the infrastructure first. They validated processes first. They aligned the licensing first. They prepared the quality system first. They ensured that the cleanroom backbone exists now, not someday.
Which means the real takeaway from this back and forth is not a debate about a line from 2020. It is the realization that the company has positioned itself to scale the moment the Eden units are validated. Not years later. Not after new facilities are built. But immediately.
That is what the filings actually show. The company never said it loudly, but the work is already done.
Thank you for answering directly. Let me stay focused on the single point you raised.
You asked why NWBO did not explicitly state “C grade fitting complete.” The reason is that they do not have to say it. Once SOW 8 was marked complete, and once Advent passed both the MIA IMP inspection and the full commercial MIA inspection, the regulatory conclusion is already in place. MHRA does not license ATMP manufacturing on plans or future intentions. They license only what is built, qualified and inspected at the time of review.
That is why the filings can openly discuss a future simplified C lab for Eden while the current licensed footprint already supports the upstream work required for L and Direct. The existence of C grade capability is a regulatory prerequisite, not a marketing statement. It sits inside the license, not inside a press release.
You already understand the SOW 8 chain and the London chain, so I will touch them only lightly. The upstream portion of SOW 8 cannot occur in B grade alone. It requires C grade space. And Specials/Compassionate Use production in London, years before Sawston required the same C grade capabilities. Both events happened. Both required functioning C grade environments. That is the factual anchor.
What this discussion has really done is bring something else to the surface that the filings never state outright but clearly imply.
NWBO has been preparing for scale long before approval.
It is visible everywhere once you look through that lens.
The phased Sawston buildout, the multiple SOW milestones, the acquisition of Advent, the Flaskworks development program, the simplified C lab design for automated scale, the redevelopment of the Grade B suites, and the internal language about preparing the facility for commercialization, all of it points to the same thing. They have already done the majority of the foundational work needed for rapid expansion once Eden is validated.
That is unusual in this space. Most companies wait for approval and then begin thinking about capacity. NWBO inverted that timeline. They built the infrastructure first. They validated processes first. They aligned the licensing first. They prepared the quality system first. They ensured that the cleanroom backbone exists now, not someday.
Which means the real takeaway from this back and forth is not a debate about a line from 2020. It is the realization that the company has positioned itself to scale the moment the Eden units are validated. Not years later. Not after new facilities are built. But immediately.
That is what the filings actually show. The company never said it loudly, but the work is already done.
Bullish
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
